1-4 of 4
Shufang Liu
Close
Save search
Sort by
Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Free
Clinical Trials & Observations
Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Carlo Gambacorti-Passerini, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley C. Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2022) 140 (17): 1845–1857.
https://doi.org/10.1182/blood.2021014586
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Free
Eunice S. Wang, Pau Montesinos, Mark D. Minden, Je-Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K. Altman, Violaine Havelange, Anne-Marie Watson, Elzbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E. Hill, Stanley Gill, Elizabeth Shima Rich, Ramon V. Tiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 700.
https://doi.org/10.1182/blood-2021-145379
Published: 2021
Journal Articles

Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT 3 Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort

Free
Jordi Esteve, MD PhD, Rik Schots, Teresa Bernal Del Castillo, MD PhD, Je-Hwan Lee, MD PhD, Eunice S. Wang, MD, Shira Dinner, MD, Mark D. Minden, MD PhD, Olga Salamero, MD, Jorge Sierra, MD, Goichi Yoshimoto, MD PhD, Kamel Laribi, MD, Janusz Halka, MD, Pau Montesinos, MD PhD, Shufang Liu, Elizabeth Shima Rich, MD PhD, Erkut Bahceci, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2736.
https://doi.org/10.1182/blood-2018-99-110976
Published: 2018
Journal Articles

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Free
Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, Joseph G. Jurcic, MD, Ellen K Ritchie, MD, Stephen A Strickland, Raoul Tibes, Jason Hill, PhD, Shufang Liu, Erkut Bahceci, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2705.
https://doi.org/10.1182/blood.V130.Suppl_1.2705.2705
Published: 2017